Skip to main content
Top
Published in: AIDS and Behavior 2/2013

01-02-2013 | Original Paper

Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials

Authors: Barbara Metch, Ian Frank, Richard Novak, Edith Swann, David Metzger, Cecilia Morgan, Debbie Lucy, Debora Dunbar, Parrie Graham, Tamra Madenwald, Gina Escamilia, Beryl Koblin

Published in: AIDS and Behavior | Issue 2/2013

Login to get access

Abstract

Enrollment of US women with sufficient risk of HIV infection into HIV vaccine efficacy trials has proved challenging. A cohort of 799 HIV-negative women, aged 18–45, recruited from three US cities was enrolled to assess recruitment strategies based on geographic risk pockets, social and sexual networks and occurrence of sexual concurrency and to assess HIV seroincidence during follow-up (to be reported later). Among enrolled women, 90 % lived or engaged in risk behaviors within a local risk pocket, 64 % had a male partner who had concurrent partners and 50 % had a male partner who had been recently incarcerated. Nearly half (46 %) were recruited through peer referral. At enrollment, 86 % of women said they were willing to participate in a vaccine efficacy trial. Results indicate that participant and partner risk behaviors combined with a peer referral recruitment strategy may best identify an at-risk cohort willing to participate in future trials.
Literature
1.
go back to reference Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008;48(1):82–9.PubMedCrossRef Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008;48(1):82–9.PubMedCrossRef
2.
go back to reference Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: project achieve. AIDS Community health initiative enroute to the vaccine effort. AIDS. 1996;10(13):1555–61.PubMedCrossRef Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: project achieve. AIDS Community health initiative enroute to the vaccine effort. AIDS. 1996;10(13):1555–61.PubMedCrossRef
3.
go back to reference Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174(5):954–61.PubMedCrossRef Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174(5):954–61.PubMedCrossRef
4.
5.
go back to reference Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344(10):720–5.PubMedCrossRef Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344(10):720–5.PubMedCrossRef
6.
go back to reference Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652–61.PubMedCrossRef Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652–61.PubMedCrossRef
7.
go back to reference Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35(3):313–22.PubMedCrossRef Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35(3):313–22.PubMedCrossRef
8.
go back to reference Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6(8):e17502.PubMedCrossRef Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6(8):e17502.PubMedCrossRef
9.
go back to reference Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET vaccine preparedness study. Am J Epidemiol. 2001;153(7):619–27.PubMedCrossRef Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET vaccine preparedness study. Am J Epidemiol. 2001;153(7):619–27.PubMedCrossRef
10.
go back to reference Seage GR III, Holte S, Gross M, et al. Case-crossover study of partner and situational factors for unprotected sex. J Acquir Immune Defic Syndr. 2002;31(4):432–9.PubMedCrossRef Seage GR III, Holte S, Gross M, et al. Case-crossover study of partner and situational factors for unprotected sex. J Acquir Immune Defic Syndr. 2002;31(4):432–9.PubMedCrossRef
11.
go back to reference Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65.PubMedCrossRef Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65.PubMedCrossRef
12.
go back to reference Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–93.PubMedCrossRef Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–93.PubMedCrossRef
13.
go back to reference Donnell D, Hughes JP, Fleming TR. Challenges in the design of HIV prevention trials in the United States. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S136–40.PubMedCrossRef Donnell D, Hughes JP, Fleming TR. Challenges in the design of HIV prevention trials in the United States. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S136–40.PubMedCrossRef
15.
go back to reference Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis. 1999;26(5):250–61.PubMedCrossRef Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis. 1999;26(5):250–61.PubMedCrossRef
16.
go back to reference Aral SO. Sexual network patterns as determinants of STD rates: paradigm shift in the behavioral epidemiology of STDs made visible. Sex Transm Dis. 1999;26(5):262–4.PubMedCrossRef Aral SO. Sexual network patterns as determinants of STD rates: paradigm shift in the behavioral epidemiology of STDs made visible. Sex Transm Dis. 1999;26(5):262–4.PubMedCrossRef
17.
go back to reference Rothenberg R, Muth SQ, Malone S, Potterat JJ, Woodhouse DE. Social and geographic distance in HIV risk. Sex Transm Dis. 2005;32(8):506–12.PubMedCrossRef Rothenberg R, Muth SQ, Malone S, Potterat JJ, Woodhouse DE. Social and geographic distance in HIV risk. Sex Transm Dis. 2005;32(8):506–12.PubMedCrossRef
18.
go back to reference Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.PubMedCrossRef Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.PubMedCrossRef
19.
go back to reference Rothenberg RB, Long DM, Sterk CE, et al. The Atlanta urban networks study: a blueprint for endemic transmission. AIDS. 2000;14(14):2191–200.PubMedCrossRef Rothenberg RB, Long DM, Sterk CE, et al. The Atlanta urban networks study: a blueprint for endemic transmission. AIDS. 2000;14(14):2191–200.PubMedCrossRef
20.
go back to reference Becker KM, Glass GE, Brathwaite W, Zenilman JM. Geographic epidemiology of gonorrhea in Baltimore, Maryland, using a geographic information system. Am J Epidemiol. 1998;147(7):709–16.PubMedCrossRef Becker KM, Glass GE, Brathwaite W, Zenilman JM. Geographic epidemiology of gonorrhea in Baltimore, Maryland, using a geographic information system. Am J Epidemiol. 1998;147(7):709–16.PubMedCrossRef
21.
go back to reference Bernstein KT, Curriero FC, Jennings JM, Olthoff G, Erbelding EJ, Zenilman J. Defining core gonorrhea transmission utilizing spatial data. Am J Epidemiol. 2004;160(1):51–8.PubMedCrossRef Bernstein KT, Curriero FC, Jennings JM, Olthoff G, Erbelding EJ, Zenilman J. Defining core gonorrhea transmission utilizing spatial data. Am J Epidemiol. 2004;160(1):51–8.PubMedCrossRef
22.
go back to reference Zenilman JM, Ellish N, Fresia A, Glass G. The geography of sexual partnerships in Baltimore: applications of core theory dynamics using a geographic information system. Sex Transm Dis. 1999;26(2):75–81.PubMedCrossRef Zenilman JM, Ellish N, Fresia A, Glass G. The geography of sexual partnerships in Baltimore: applications of core theory dynamics using a geographic information system. Sex Transm Dis. 1999;26(2):75–81.PubMedCrossRef
23.
go back to reference Potterat JJ, Rothenberg RB, Woodhouse DE, Muth JB, Pratts CI, Fogle JS. Gonorrhea as a social disease. Sex Transm Dis. 1985;12(1):25–32.PubMedCrossRef Potterat JJ, Rothenberg RB, Woodhouse DE, Muth JB, Pratts CI, Fogle JS. Gonorrhea as a social disease. Sex Transm Dis. 1985;12(1):25–32.PubMedCrossRef
24.
go back to reference De P, Singh AE, Wong T, Yacoub W, Jolly AM. Sexual network analysis of a gonorrhoea outbreak. Sex Transm Infect. 2004;80(4):280–5.PubMedCrossRef De P, Singh AE, Wong T, Yacoub W, Jolly AM. Sexual network analysis of a gonorrhoea outbreak. Sex Transm Infect. 2004;80(4):280–5.PubMedCrossRef
25.
go back to reference Binson D, Woods WJ, Pollack L, Paul J, Stall R, Catania JA. Differential HIV risk in bathhouses and public cruising areas. Am J Public Health. 2001;91(9):1482–6.PubMedCrossRef Binson D, Woods WJ, Pollack L, Paul J, Stall R, Catania JA. Differential HIV risk in bathhouses and public cruising areas. Am J Public Health. 2001;91(9):1482–6.PubMedCrossRef
26.
go back to reference Watts CH, May RM. The influence of concurrent partnerships on the dynamics of HIV/AIDS. Math Biosci. 1992;108(1):89–104.PubMedCrossRef Watts CH, May RM. The influence of concurrent partnerships on the dynamics of HIV/AIDS. Math Biosci. 1992;108(1):89–104.PubMedCrossRef
27.
go back to reference Morris M, Zavisca J, Dean L. Social and sexual networks: their role in the spread of HIV/AIDS among young gay men. AIDS Educ Prev. 1995;7(5 Suppl):24–35.PubMed Morris M, Zavisca J, Dean L. Social and sexual networks: their role in the spread of HIV/AIDS among young gay men. AIDS Educ Prev. 1995;7(5 Suppl):24–35.PubMed
28.
go back to reference Youm Y, Laumann EO. Social network effects on the transmission of sexually transmitted diseases. Sex Transm Dis. 2002;29(11):689–97.PubMedCrossRef Youm Y, Laumann EO. Social network effects on the transmission of sexually transmitted diseases. Sex Transm Dis. 2002;29(11):689–97.PubMedCrossRef
29.
go back to reference Adimora AA, Schoenbach VJ, Martinson FE, Donaldson KH, Stancil TR, Fullilove RE. Concurrent partnerships among rural African Americans with recently reported heterosexually transmitted HIV infection. J Acquir Immune Defic Syndr. 2003;34(4):423–9.PubMedCrossRef Adimora AA, Schoenbach VJ, Martinson FE, Donaldson KH, Stancil TR, Fullilove RE. Concurrent partnerships among rural African Americans with recently reported heterosexually transmitted HIV infection. J Acquir Immune Defic Syndr. 2003;34(4):423–9.PubMedCrossRef
30.
go back to reference Adimora AA, Schoenbach VJ, Taylor EM, Khan MR, Schwartz RJ. Concurrent partnerships, nonmonogamous partners, and substance use among women in the United States. Am J Public Health. 2011;101(1):128–36.PubMedCrossRef Adimora AA, Schoenbach VJ, Taylor EM, Khan MR, Schwartz RJ. Concurrent partnerships, nonmonogamous partners, and substance use among women in the United States. Am J Public Health. 2011;101(1):128–36.PubMedCrossRef
31.
go back to reference Tanser F, Barnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet. 2011;378(9787):247–55.PubMedCrossRef Tanser F, Barnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet. 2011;378(9787):247–55.PubMedCrossRef
32.
go back to reference Adimora AA, Schoenbach VJ, Floris-Moore MA. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med. 2009;37(5):468–71.PubMedCrossRef Adimora AA, Schoenbach VJ, Floris-Moore MA. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med. 2009;37(5):468–71.PubMedCrossRef
33.
go back to reference Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the United States. Am J Public Health. 2007;97(12):2230–7.PubMedCrossRef Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the United States. Am J Public Health. 2007;97(12):2230–7.PubMedCrossRef
34.
go back to reference Grinstead OA, Faigeles B, Comfort M, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;41(2):63–80.PubMedCrossRef Grinstead OA, Faigeles B, Comfort M, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;41(2):63–80.PubMedCrossRef
35.
go back to reference CDC. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence—24 cities, United States, 2006–2007. MMWR Morb Mortal Wkly Rep 2011; 60(31):1045–1049. CDC. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence—24 cities, United States, 2006–2007. MMWR Morb Mortal Wkly Rep 2011; 60(31):1045–1049.
36.
go back to reference Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.PubMedCrossRef Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.PubMedCrossRef
37.
go back to reference Thomas JC, Sampson LA. High rates of incarceration as a social force associated with community rates of sexually transmitted infection. J Infect Dis. 2005;191(Suppl 1):S55–60.PubMedCrossRef Thomas JC, Sampson LA. High rates of incarceration as a social force associated with community rates of sexually transmitted infection. J Infect Dis. 2005;191(Suppl 1):S55–60.PubMedCrossRef
38.
go back to reference Gorbach PM, Drumright LN, Holmes KK. Discord, discordance, and concurrency: comparing individual and partnership-level analyses of new partnerships of young adults at risk of sexually transmitted infections. Sex Transm Dis. 2005;32(1):7–12.PubMedCrossRef Gorbach PM, Drumright LN, Holmes KK. Discord, discordance, and concurrency: comparing individual and partnership-level analyses of new partnerships of young adults at risk of sexually transmitted infections. Sex Transm Dis. 2005;32(1):7–12.PubMedCrossRef
39.
go back to reference Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005;191(Suppl 1):S115–22.PubMedCrossRef Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005;191(Suppl 1):S115–22.PubMedCrossRef
40.
go back to reference Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305–12.PubMedCrossRef Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305–12.PubMedCrossRef
41.
go back to reference Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV risk behaviors of male and female jail inmates prior to incarceration and one year post-release. AIDS Behav 2011 (in press). Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV risk behaviors of male and female jail inmates prior to incarceration and one year post-release. AIDS Behav 2011 (in press).
42.
go back to reference Frew PM, Archibald M, Hixson B, del Rio C. Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011;29(36):6136–43.PubMedCrossRef Frew PM, Archibald M, Hixson B, del Rio C. Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011;29(36):6136–43.PubMedCrossRef
43.
go back to reference Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41(2):210–7.PubMedCrossRef Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41(2):210–7.PubMedCrossRef
44.
go back to reference Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235–42.PubMedCrossRef Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235–42.PubMedCrossRef
45.
go back to reference Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr. 2001;26(1):63–71.PubMed Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr. 2001;26(1):63–71.PubMed
46.
go back to reference Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17(3):253–67.PubMedCrossRef Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17(3):253–67.PubMedCrossRef
47.
go back to reference Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12(7):785–93.PubMedCrossRef Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12(7):785–93.PubMedCrossRef
48.
go back to reference Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at “high risk” of HIV infection. Vaccine. 2011;29(36):6130–5.PubMedCrossRef Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at “high risk” of HIV infection. Vaccine. 2011;29(36):6130–5.PubMedCrossRef
49.
go back to reference Buchbinder SP, Metch B, Holte Se, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–12.PubMedCrossRef Buchbinder SP, Metch B, Holte Se, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–12.PubMedCrossRef
50.
go back to reference Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine. 2011;29:5850–9.PubMedCrossRef Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine. 2011;29:5850–9.PubMedCrossRef
51.
go back to reference Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359–64.PubMedCrossRef Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359–64.PubMedCrossRef
Metadata
Title
Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials
Authors
Barbara Metch
Ian Frank
Richard Novak
Edith Swann
David Metzger
Cecilia Morgan
Debbie Lucy
Debora Dunbar
Parrie Graham
Tamra Madenwald
Gina Escamilia
Beryl Koblin
Publication date
01-02-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0351-6

Other articles of this Issue 2/2013

AIDS and Behavior 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine